Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 5/20 | 0.44 |
| ▸ | BRS3 | P32247 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30145185 | 0.86 | MARS2 (0.61) | MARS2HSP90AA1HSP90AB1CRHR1 | |
| SCHEMBL20596151 | 0.86 | MARS2 (0.61) | MARS2HSP90AA1HSP90AB1CRHR1 | |
| SCHEMBL20596185 | 0.74 | MARS2 (0.49) | MARS2CRHR1AMY1A | |
| SCHEMBL20595984 | 0.74 | MARS2 (0.75) | MARS2 | |
| SCHEMBL20596138 | 0.71 | MARS2 (0.79) | MARS2GRIN1GRIN2BHSP90AA1HSP90AB1 | |
| SCHEMBL23419328 | 0.69 | MARS2 (0.56) | MARS2 | |
| SCHEMBL30145178 | 0.69 | MARS2 (0.62) | MARS2GRIN1GRIN2BHSP90AA1HSP90AB1 | |
| SCHEMBL20596061 | 0.69 | MARS2 (0.62) | MARS2GRIN1GRIN2BHSP90AA1HSP90AB1 | |
| SCHEMBL20595968 | 0.67 | AMY1A (0.43) | MARS2BRS3GRIN1GRIN2BAMY1A | |
| SCHEMBL20596612 | 0.67 | MARS2 (0.57) | MARS2BRS3HSP90AA1HSP90AB1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885BRS3 4505/4885GRIN1 1189/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885BRS3 4478/4885GRIN1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.